In the News

Organoids Touted as Future of Brain Disorder R&D as AxoSim Scoops Up Tech from Vyant Subsidiary

October 24, 2023
Loading the Elevenlabs Text to Speech AudioNative Player...
As Vyant Bio continues its wind-down, the neuroscience research assets of its subsidiary StemoniX have officially been picked up by AxoSim, a New Orleans-based drug discovery biotech.
28bio’s Endurance Study Meets Primary Endpoint, Showing CNS-3D Brain Organoids Predict Clinical Seizure Liability
28bioGRANT for Neurodegenerative Disease
The 28bioGRANT for Neurodegenerative Disease is designed to assist academic researchers in their pursuit to understand the human biological underpinnings of these diseases and translate those insights into potential therapeutic strategies.
Organoid Neurotoxicity Testing Embraced by FDA and NIH
Scientists and regulators have long acknowledged the weaknesses in traditional methods used to identify drugs that may harm the central nervous system.